193 related articles for article (PubMed ID: 27993997)
1. Letter: Vedolizumab in Pregnancy.
Sheridan J; Cullen G; Doherty G
J Crohns Colitis; 2017 Aug; 11(8):1025-1026. PubMed ID: 27993997
[No Abstract] [Full Text] [Related]
2. Healthy Mum - Healthy Baby? Safety of Vedolizumab During Periconceptual Period.
Pietrzak A; Skoczylas K; Mróz A
J Crohns Colitis; 2020 Oct; 14(10):1496-1497. PubMed ID: 32215651
[No Abstract] [Full Text] [Related]
3. Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.
Zoet ID; de Boer NK; de Meij TG
J Crohns Colitis; 2016 Mar; 10(3):373-4. PubMed ID: 26574489
[No Abstract] [Full Text] [Related]
4. Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
Hendy P; Hart A
Aliment Pharmacol Ther; 2015 Jan; 41(1):149. PubMed ID: 25483435
[No Abstract] [Full Text] [Related]
5. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
6. Using Vedolizumab to Treat Severe Sweet's Syndrome in a Patient With Ulcerative Colitis.
Belvis Jiménez M; Maldonado Pérez B; Argüelles-Arias F
J Crohns Colitis; 2018 Aug; 12(9):1134-1135. PubMed ID: 29788419
[No Abstract] [Full Text] [Related]
7. Real-world evidence for vedolizumab: Understanding the landscape.
Lawrance IC; Pulusu SSR
J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():28-29. PubMed ID: 30187556
[No Abstract] [Full Text] [Related]
8. Nodular vasculitis during treatment with vedolizumab in a patient with ulcerative colitis.
Abbenante D; Merli Y; Misciali C; Sacchelli L; Bardazzi F
Australas J Dermatol; 2022 Feb; 63(1):131-132. PubMed ID: 34817061
[No Abstract] [Full Text] [Related]
9. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
10. Response to vedolizumab for children with steroid-refractory Ulcerative Colitis unresponsive to anti-TNF.
Wiskin AE; Paul SP; Spray CH
Acta Paediatr; 2019 Jul; 108(7):1359-1360. PubMed ID: 30788859
[No Abstract] [Full Text] [Related]
11. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
12. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
Tsai HH; Black C
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
[TBL] [Abstract][Full Text] [Related]
13. Should we use vedolizumab as mono or combo therapy in ulcerative colitis?
Hedin C; Halfvarson J
Best Pract Res Clin Gastroenterol; 2018; 32-33():27-34. PubMed ID: 30060935
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 acquisition in a man with ulcerative colitis on anti-α4β7 mAb vedolizumab treatment.
Gunst JD; Schleimann MH; Pahus MH; Østergaard L; Tolstrup M; Søgaard OS
AIDS; 2020 Sep; 34(11):1689-1692. PubMed ID: 32769767
[No Abstract] [Full Text] [Related]
15. Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy.
Roblin X; Paul S; Ben-Horin S
J Crohns Colitis; 2018 Feb; 12(3):379-380. PubMed ID: 29088342
[No Abstract] [Full Text] [Related]
16. Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.
de Freitas LF; Feitosa MR; Féres O; Parra RS
Inflamm Bowel Dis; 2021 Jan; 27(2):e15-e17. PubMed ID: 33048114
[No Abstract] [Full Text] [Related]
17. Resolution of CMV Infection in the Bowel on Vedolizumab Therapy.
Rawa-Gołębiewska A; Lenarcik M; Zagórowicz E
J Crohns Colitis; 2019 Sep; 13(9):1234-1235. PubMed ID: 30860256
[No Abstract] [Full Text] [Related]
18. Treatment of Ulcerative Colitis and Seronegative Inflammatory Spondyloarthritis With Vedolizumab and Tofacitinib.
Lee JA; Magavi PR; Konijeti GG
Inflamm Bowel Dis; 2020 Oct; 26(11):e146. PubMed ID: 32592470
[No Abstract] [Full Text] [Related]
19. Management of Ulcerative Colitis Using Vedolizumab After Liver Transplantation for Primary Sclerosing Cholangitis.
Meszaros M; Pageaux GP; Altwegg R
J Crohns Colitis; 2016 Feb; 10(2):236. PubMed ID: 26449788
[No Abstract] [Full Text] [Related]
20. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
Pouillon L; Van Stappen J; Bossuyt P; Danese S; Peyrin-Biroulet L
Best Pract Res Clin Gastroenterol; 2018; 32-33():17-25. PubMed ID: 30060934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
